Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors
Summary
USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.
What changed
USPTO published Yuhan Corporation's patent application US20260098038A1 covering novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran compounds with inhibitory activity against glucosylceramide synthase (GCS). The patent claims the compounds, their salts, pharmaceutical compositions containing them, and methods of use for treating GCS-associated diseases including Gaucher disease, Fabry disease, Tay-Sachs disease, and Parkinson's disease. The application (filed December 12, 2025) was published April 9, 2026 under CPC classification C07D 471/08.
Pharmaceutical companies developing treatments for lysosomal storage disorders or Parkinson's disease should review this patent for freedom-to-operate considerations. Researchers and drug developers in these therapeutic areas may find opportunities for licensing discussions with Yuhan Corporation.
What to do next
- Monitor for patent prosecution updates
- Review for freedom-to-operate implications if developing GCS inhibitors
- Assess licensing opportunities for affected therapeutic areas
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
Application US20260098038A1 Kind: A1 Apr 09, 2026
Assignee
YUHAN CORPORATION
Inventors
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Ji-Hye KIM
Abstract
Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, where the. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
CPC Classifications
C07D 471/08
Filing Date
2025-12-12
Application No.
19418159
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.